Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, Müller M, Ehrlich H, Barrett PN. Crowe BA, et al. Among authors: zeitlinger m. Vaccine. 2010 Dec 16;29(2):166-73. doi: 10.1016/j.vaccine.2010.10.065. Epub 2010 Nov 4. Vaccine. 2010. PMID: 21055500
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P. Ehrlich HJ, et al. Among authors: zeitlinger m. J Infect Dis. 2009 Oct 1;200(7):1113-8. doi: 10.1086/605608. J Infect Dis. 2009. PMID: 19712040 Clinical Trial.
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN. Ehrlich HJ, et al. Among authors: zeitlinger m. Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1. Vaccine. 2012. PMID: 22475864 Clinical Trial.
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. van der Velden MV, et al. Among authors: zeitlinger m. Vaccine. 2012 Sep 21;30(43):6127-35. doi: 10.1016/j.vaccine.2012.07.077. Epub 2012 Aug 8. Vaccine. 2012. PMID: 22884662 Clinical Trial.
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN. Wressnigg N, et al. Among authors: zeitlinger m. Lancet Infect Dis. 2013 Aug;13(8):680-9. doi: 10.1016/S1473-3099(13)70110-5. Epub 2013 May 10. Lancet Infect Dis. 2013. PMID: 23665341 Clinical Trial.
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, Zeitlinger M, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G. van der Velden MV, et al. Among authors: zeitlinger m. Clin Vaccine Immunol. 2014 Jun;21(6):867-76. doi: 10.1128/CVI.00065-14. Epub 2014 Apr 16. Clin Vaccine Immunol. 2014. PMID: 24739978 Free PMC article. Clinical Trial.
A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
Wressnigg N, Barrett PN, Pöllabauer EM, O'Rourke M, Portsmouth D, Schwendinger MG, Crowe BA, Livey I, Dvorak T, Schmitt B, Zeitlinger M, Kollaritsch H, Esen M, Kremsner PG, Jelinek T, Aschoff R, Weisser R, Naudts IF, Aichinger G. Wressnigg N, et al. Among authors: zeitlinger m. Clin Vaccine Immunol. 2014 Nov;21(11):1490-9. doi: 10.1128/CVI.00406-14. Epub 2014 Sep 3. Clin Vaccine Immunol. 2014. PMID: 25185574 Free PMC article. Clinical Trial.
335 results